3E Bioventures
VC Fund
Beijing, China
3E Bioventures is a VC fund in Beijing focused on Biotechnology and Health Care. 3E Bioventures Capital is a healthcare focused venture investment fund. The core 3E investment team members are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China. The 3E team combines good global industry perspectives with practical on the ground Chinaexperiences, the team’s past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. 3E Bioventures Capital currently manages both RMB and US Dollar funds, investing in early and growing stage companies in China and overseas. They believe in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years. They aim to leverage their healthcare expertise and experience to ride this historic opportunity, to help build successful healthcare ventures and technologies, to generate good return for their investors, and at the same time, to build 3E Bioventures into a significant international healthcare investment brand.
- Total investments:
- 66
- Last investment:
- Lead investor:
- 36%
- Fund size:
- $200M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries 3E Bioventures invests in
Stages 3E Bioventures invests in
Countries 3E Bioventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $6.5M–$50M
- Series B
- $13M–$85M
- Series C
- $29M–$150M
Investment Focus
Industry
- Biotechnology 30 (45%)
- Health Care 25 (38%)
- Medical 20 (30%)
- Biopharma 13 (20%)
- Therapeutics 9 (14%)
Stage
- Series A 23 (35%)
- Series B 16 (24%)
- Series C 7 (11%)
- Angel 4 (6%)
- Seed 3 (5%)
Country
- China 24 (36%)
- United States 21 (32%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Karen Liu
Founding Partner
|
Founding Partner | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tianhu Technology
|
Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. | Series A / Jul 13, 2026 | |
Junhemeng Biopharmaceutical
|
Junhemeng is a research and development company of recombinant protein drugs. | $29.5M / Series C / Jun 08, 2026 | |
Yimou Bio
|
Yimou Bio focuses on the research and development of small nucleic acid drugs for ophthalmology, aiming to create innovative therapies for the treatment of eye diseases and improve patient outcomes through advanced biotechnology solutions. | Angel / May 09, 2026 | |
|
Tianhu Technology
|
Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. | $29M / Series A / Mar 16, 2026 | |
OncoC4
|
OncoC4 is a clinical-stage biotechnology company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer and neurodegenerative disease. | $50M / Series B / Oct 02, 2025 | |
Rapafusyn Pharmaceuticals
|
Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle. The company develops novel pharmaceuticals to treat patients having diseases and fulfill other unmet medical needs. | $16M / Series A / Sep 04, 2025 | |
Xijian Technology
|
Xijian Technology is committed to advancing the industrialization of innovative human biomechanics imaging technology. It focuses on health disciplines such as sports rehabilitation, dermatology and beauty, and disease diagnosis and treatment. | $1.4M / Series A / Jul 16, 2025 | |
UltraClear
|
UltraClear is a skincare clinic that provides facial rejuvenation solutions for the treatment of all skin types. | $23M / Series B / May 29, 2025 | |
Matwings Technology
|
Matwings is a biotechnology industry that moves evolution methods to design functionally optimized proteins by leveraging a proprietary. | Series A / Nov 15, 2024 | |
|
Tianhu Technology
|
Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. | $13.8M / Series A / Nov 15, 2024 | |
| See all 66 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does 3E Bioventures invest in?
3E Bioventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 66 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is 3E Bioventures's check size?
3E Bioventures typically joins rounds of $6.5M–$50M at Series A, $13M–$85M at Series B and $29M–$150M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds 3E Bioventures participates in.
How do I contact 3E Bioventures?
Public channels for 3E Bioventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 3E Bioventures?
The team at 3E Bioventures includes Karen Liu (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
